Top

Global Central Nervous System Disorders Therapeutics Market 2016-2020

Category : Pharmaceuticals  | Published Date : Sept-2016 | Pages : 147
enquire GET DISCOUNT
About CNS disorders

CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

Technavio’s analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA

Technavio's report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis

Other prominent vendors 
• AB Science
• AbbVie
• Abital Pharma
• Acorda Therapeutics
• Active Biotech
• Adamas Pharmaceuticals
• Addex Therapeutics
• Akorn
• Alcobra
• Alexza Pharmaceuticals
• Alkermes
• Amarantus
• Aprecia Pharmaceuticals
• Archer Pharmaceuticals
• Astellas
• AstraZeneca
• Aurobindo Pharma
• Auspex Pharmaceuticals
• Avanir Pharmaceuticals
• Biscayne Pharmaceuticals
• Boehringer Ingelheim
• Cerecor
• Concordia
• Convergence Pharmaceuticals
• Curemark
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• Dart NeuroScience
• Delpor
• Desitin Arzneimittel
• D-Pharm
• Edgemont Pharmaceuticals
• Endo International
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre-Kramer Pharmaceuticals
• Forum Pharmaceuticals
• Gedeon Richter
• Glenmark
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• H. Lundbeck
• Hisamitsu
• Impax
• Insero Health
• INSYS Therapeutics
• Intellipharmaceutics
• Intra-Cellular Therapies
• Ipsen
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals
• Lupin
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda AB
• Merck
• Mitsubishi Tanabe
• MSI Methylation Sciences
• Mylan
• Naurex
• Neuralstem
• Neurelis 
• Neurovance
• Nobelpharma
• Noven Pharmaceuticals
• Omeros
• Opexa
• Opko Health
• Orion
• Ophelia Pharmaceutical
• Otsuka Pharmaceuticals
• Palobiofarma
• Par Pharmaceuticals
• Pierre Fabre
• Prana Biotechnology
• Raptor Pharmaceutical
• Reviva Pharmaceuticals 
• SAGE Therapeutics
• Sanofi
• SciFlour
• Sedor Pharmaceuticals
• Shire
• Siena Biotech
• SK Biopharmaceuticals
• SOM Biotech
• Somerset Pharmaceuticals
• STADA Arzneimittel
• Sun Pharmaceuticalc
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Suven
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Tris Pharma
• Turing Pharmaceuticals
• UCB
• US WorldMeds
• Valeant Pharmaceuticals
• Zinfandel Pharmaceuticals
• Zogenix

Market driver 
• New DMD approvals for AD, PD, and MS 
• For a full, detailed list, view our report 

Market challenge 
• High failure rates of late-stage products in clinical trials 
• For a full, detailed list, view our report 

Market trend 
• Increased uptake of new-generation drugs 
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Pipeline portfolio
• Phase III pipeline portfolio: Global CNS disorders therapeutics market
• Phase II pipeline portfolio: Global CNS disorders therapeutics market
• Phase I pipeline portfolio: Global CNS disorders therapeutics market
• Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of disease
• Global depression drugs market
• Global MS drugs market
• Global schizophrenia drugs market
• Global bipolar disorder therapeutics market
• Global AD drugs market
• Global epilepsy drugs market
• Global PD drugs market
PART 08: Geographical segmentation
• CNS disorders therapeutics market in Americas
• CNS disorders therapeutics market in EMEA
• CNS disorders therapeutics market in APAC
PART 09: Market drivers
• Special regulatory designations for CNS disorders
• New DMD approvals for AD, PD, and MS
• Development of novel therapeutics using innovative technologies
• High growth potential of mAbs
PART 10: Impact of drivers
PART 11: Market challenges
• High failure rates of late-stage products in clinical trials
• Growing use of non-invasive neuromodulation and seizure management devices
• Unavailability of standard diagnostic methods
• Increase in rehabilitation programs
• Social stigma associated with CNS diseases
PART 12: Impact of drivers and challenges
PART 13: Market trends
• Popularity of me-too drugs
• Increased uptake of new-generation drugs
• Reformulation of marketed drugs
• Focus on regenerative therapies for CNS disorders
• Increase in use of LAI antipsychotics
PART 14: Vendor landscape
• Competitive scenario
• Key news3
• GlaxoSmithKline7
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
PART 16: Explore Technavio
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top